Arca
Skip to content
Tools
Tools

Glomerulopathy

Drug research and approvals for glomerulopathy: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 34 studies of glomerulopathy are recruiting on ClinicalTrials.gov, Health Canada has authorized 5 drug trials for it since 2013, FDA has 3 approved and 3 open orphan designations naming it, and the EU has 1 authorised medicine for it.

  • Recruiting worldwide: 34
  • Trials authorized in Canada: 5
  • FDA orphan approvals: 3
  • EU medicines: 1

Recruiting now

Newest posted first, of 34 recruiting on ClinicalTrials.gov ↗

Trials authorized in Canada

Newest first; search them all in Canada trials
Jul 28, 2026A 2-year, single-arm, multi-center study to explore the efficacy and safety of pegcetacoplan in preventing disease recurrence in adolescent and adult kidney…Pegcetacoplan (APL-2)Swedish Orphan BiovitrumPending
Sep 12, 2023An open-label, non-randomized extension study to evaluate the long-term efficacy, safety and tolerability of iptacopan (LNP023) in C3 glomerulopathy or…Iptacopan (LNP023)Novartis PharmaceuticalsOngoing
May 18, 2022A phase 3, randomized, placebo-controlled, double-blinded, multicenter study to evaluate the efficacy and safety of pegcetacoplan in patients with C3…Pegcetacoplan (APL-2)Apellis PharmaceuticalsClosed
Jun 9, 2021A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in complement 3…Iptacopan (LNP023)Novartis PharmaceuticalsOngoing
Dec 13, 2017A randomized, double-blind, placebo-controlled phase 2 study to evaluate the safety and efficacy of avacopan (CCX168) in patients with C3 glomerulopathyAvacopan (CCX168)AmgenClosed

FDA orphan designations

Approved first, then open designations, newest first
Aug 20, 2026EmpaveliTreatment of adult and pediatric patients aged 12 years and older with C3 glomerulopathy (C3G), to reduce proteinuria and the loss of…Apellis Pharmaceuticals, Inc., a wholly owned subsidiary of Biogen, MA, Inc.Approved
Jul 28, 2025EmpaveliTreatment of adult and pediatric patients aged 12 years and older with C3 glomerulopathy (C3G), to reduce proteinuriaApellis Pharmaceuticals, Inc., a wholly owned subsidiary of Biogen, MA, Inc.Approved
Mar 20, 2025FabhaltaTreatment of adults with complement 3 glomerulopathy (C3G), to reduce proteinuriaNovartis Pharmaceuticals CorporationApproved
Oct 16, 2025Chemically synthesized double-stranded oligonucleotide…Treatment of complement 3 glomerulopathySanegene Bio USA Inc.Designated
Nov 22, 2022Synthetic double-strand small interfering ribonucleic acid…Treatment of C3 GlomerulopathySilence Therapeutics plcDesignated
Nov 16, 2015S3,S13-cyclo(D-tyrolsyl-L-isoleucyl-L-cysteinyl-L-valyl-1-me…Treatment of C3 glomerulopathy.Amyndas Pharmaceuticals S.ADesignated

Medicines authorised in the EU

Newest first
AuthorisedMedicineHolderEPAR
May 17, 2024FabhaltaIptacopan · orphanNovartis Europharm LimitedEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.